Sec Form 3 Filing - Warren Eric @ Esperion Therapeutics, Inc. - 2022-03-01

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 3
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Warren Eric
2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
Chief Commercial Officer
(Last) (First) (Middle)
C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150
3. Date of Earliest Transaction (MM/DD/YY)
03/01/2022
(Street)
ANN ARBOR, MI48108
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11,207( 1 ) D
Common Stock 5,899( 2 ) D
Common Stock 24,000( 3 ) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Warren Eric
C/O ESPERION THERAPEUTICS, INC.
3891 RANCHERO DRIVE, SUITE 150
ANN ARBOR, MI48108
Chief Commercial Officer
Signatures
/s/ Richard B. Bartram, by power of attorney 03/09/2022
Signature of Reporting Person Date
Explanation of Responses:
( 1 )These shares were acquired pursuant to a restricted stock unit award under the 2017 Inducement Equity Plan. Each restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. The restricted stock unit vests over a four-year period with 25% of the shares underlying the option vesting on the one-year anniversary of February 15, 2021, and 1/16th vesting on each quarterly anniversary of such date thereafter, subject to continued employment through each such date.
( 2 )These shares were acquired pursuant to a restricted stock unit award under the Amended and Restated 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. The restricted stock unit vests over a four-year period with 25% of the shares underlying the option vesting on the one-year anniversary of July 15, 2021, and 1/16th vesting on each quarterly anniversary of such date thereafter, subject to continued employment through each such date.
( 3 )These shares were acquired pursuant to a performance-based restricted stock unit award under the Amended and Restated 2013 Stock Option and Incentive Plan. Each performance-based restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. The awards will vest as follows: 50% shall vest upon CVOT public presentation of results; and 50% shall vest upon obtaining approval for cardiovascular risk reduction into the U.S. label.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.